UCFA
PCRX icon

United Capital Financial Advisors’s Pacira BioSciences PCRX Stock Holding History

United Capital Financial Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-5,880
Closed -$253K – 1389
2018
Q4 		$253K Buy
5,880
+209
+4% +$9.76K ﹤0.01% 1122
2018
Q3 		$279K Buy
+5,671
New +$245K ﹤0.01% 1135

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

United Capital Financial Advisors's PCRX Position: Q1 2019 in Review

United Capital Financial Advisors sold out of Pacira BioSciences (PCRX) in Q1 2019, closing a stake of 5,880 shares — an estimated $253K sold.

United Capital Financial Advisors first reported a position in PCRX in Q3 2018 and held it in 2 quarters. The position peaked at $279K in Q3 2018. 210 funds tracked by Wall St. Rank hold PCRX as of Q1 2019.

  • United Capital Financial Advisors reported no remaining Pacira BioSciences position as of Q1 2019 after selling out during the quarter.
  • United Capital Financial Advisors sold 5,880 Pacira BioSciences shares in Q1 2019, an estimated $253K.
  • United Capital Financial Advisors first reported a position in Pacira BioSciences in Q3 2018 and held it in 2 quarters.
  • United Capital Financial Advisors's Pacira BioSciences position peaked at $279K in Q3 2018.
  • 210 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2019.

Based on United Capital Financial Advisors's 13F filing for Q1 2019, filed 14 May 2019.